IndraLab
Statements
Geldanamycin inhibits RIPK1. 4 / 4
|
1
3
reach
"Key Points * Geldanamycin (GM) disrupts RIPK1 and selectively inhibits the TNFR1 triggered NF-kappaB activation signaling pathway while enhancing the apoptosis signaling pathway upon TNFalpha stimulation, thereby redressing the balance between these two opposing signals in a human rheumatoid synovial cell line, MH7A."